The financials
Prestige Consumer Healthcare Inc. by the numbers
Prestige Consumer Healthcare Inc. (PBH) reported revenue of $282M in Q4 2026 (quarter ended March 31, 2026), down 5.0% from the same quarter a year earlier. That came with a gross margin of 52% and net income of $54M (19% of revenue). For the full year FY2026, revenue was $1.09B (−4.3% year on year) and net income $190M. Its largest product in 2026-Q2 was Womens Health at $47M, 20.4% of the disclosed total, just ahead of Gastrointestinal at 20.4%.
| Income statement | Q4 2026 | Q4 2025 | Change |
|---|---|---|---|
| Revenue | $282M | $297M | −5.0% |
| Gross profit | $146M | $170M | −14% |
| Operating income | $75M | $88M | −15% |
| Net income | $54M | $50M | +7.6% |
| Diluted EPS | $1.13 | $1.01 | +12% |
| Product | Revenue | Share |
|---|---|---|
| Womens Health | $47M | 20% |
| Gastrointestinal | $47M | 20% |
| Dermatologicals | $31M | 13% |
| Eye And Ear Care | $28M | 12% |
| Pain Relief | $26M | 11% |
| Oral Care | $18M | 8.0% |
| Cough Cold And Allergy | $16M | 6.7% |
| Wellness Sleep Other | $13M | 5.4% |
| Product And Service Other | $5.4M | 2.3% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $231.6M (-1.9%)
Product And Service Other grew +2033% year on yearWomens Health -5.1% year on year
Segment Latestquarter on quarteryear on year
- Womens Health$47.2M$47.2MQoQ -8.8%year on year -5.1%-8.8%-5.1%
- Gastrointestinal$47.1M$47.1MQoQ +6.6%year on year +7.9%+6.6%+7.9%
- Dermatologicals$30.6M$30.6MQoQ +11%year on year +9.9%+11%+9.9%
- Eye And Ear Care$28.3M$28.3MQoQ -20%year on year +2.0%-20%+2.0%
- Pain Relief$26.2M$26.2MQoQ -year on year -3.8%--3.8%
- Oral Care$18.5M$18.5MQoQ -21%year on year +1.7%-21%+1.7%
- Cough Cold And Allergy$15.6M$15.6MQoQ -year on year +17%-+17%
- Wellness Sleep Other$12.6M$12.6MQoQ -year on year +166%-+166%
- Product And Service Other$5.4M$5.4MQoQ +1247%year on year +2033%+1247%+2033%
- Analgesics--QoQ -year on year ---
- Cough And Cold--QoQ -year on year ---
- Other Otc--QoQ -year on year ---
Drug Manufacturers - Specialty & Generic
Ranks #9 of 28 by Smart Score